Title |
Eslicarbazepine acetate add-on for drug-resistant partial epilepsy
|
---|---|
Published in |
Cochrane database of systematic reviews, January 2011
|
DOI | 10.1002/14651858.cd008907.pub2 |
Pubmed ID | |
Abstract |
The majority of people with epilepsy will have a good prognosis, but up to 30% of patients will continue to have seizures despite several regimens of antiepileptic drugs. In this review we summarized the current evidence regarding eslicarbazepine acetate (ESL) when used as an add-on treatment for drug-resistant partial epilepsy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 15 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 4 | 27% |
Student > Master | 3 | 20% |
Student > Doctoral Student | 2 | 13% |
Researcher | 2 | 13% |
Professor > Associate Professor | 1 | 7% |
Other | 0 | 0% |
Unknown | 3 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 53% |
Nursing and Health Professions | 2 | 13% |
Chemistry | 1 | 7% |
Biochemistry, Genetics and Molecular Biology | 1 | 7% |
Unknown | 3 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 February 2012.
All research outputs
#15,239,825
of 22,659,164 outputs
Outputs from Cochrane database of systematic reviews
#10,763
of 12,296 outputs
Outputs of similar age
#140,033
of 180,269 outputs
Outputs of similar age from Cochrane database of systematic reviews
#67
of 90 outputs
Altmetric has tracked 22,659,164 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 12,296 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 30.3. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 180,269 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 90 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.